C Casetta, P Santosh, R Bayley, J Bisson, S Byford, C Dixon, R J Drake, R Elvins, R Emsley, N Fung, D Hayes, O Howes, A James, K James, R Jones, H Killaspy, B Lennox, L Marchant, P McGuire, E Oloyede, M Rogdaki, R Upthegrove, J Walters, A Egerton, J H MacCabe
BACKGROUND: Clozapine is an antipsychotic drug with unique efficacy, and it is the only recommended treatment for treatment-resistant schizophrenia (TRS: failure to respond to at least two different antipsychotics). However, clozapine is also associated with a range of adverse effects which restrict its use, including blood dyscrasias, for which haematological monitoring is required. As treatment resistance is recognised earlier in the illness, the question of whether clozapine should be prescribed in children and young people is increasingly important...
February 14, 2024: BMC Psychiatry